Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
Background/Aims Daratumumab has shown an encouraging antitumor effect in patients with multiple myeloma (MM), and was known to alter the immune properties by off-targeting immunosuppressive cells. Here, we aimed to evaluate the change in absolute lymphocyte count (ALC) as a surrogate marker for pred...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Association of Internal Medicine
2023-03-01
|
| Series: | The Korean Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://www.kjim.org/upload/kjim-2022-183.pdf |
| _version_ | 1827999654771425280 |
|---|---|
| author | Hee Jeong Cho Jae-Cheol Jo Yoo Jin Lee Myung Won Lee Do Young Kim Ho Jin Shin Sung Nam Im Ji Hyun Lee Sung Hwa Bae Young Rok Do Won Sik Lee Min Kyung Kim Jina Jung Jung Min Lee Ju-Hyung Kim Dong Won Baek Sang-Kyun Sohn Joon Ho Moon |
| author_facet | Hee Jeong Cho Jae-Cheol Jo Yoo Jin Lee Myung Won Lee Do Young Kim Ho Jin Shin Sung Nam Im Ji Hyun Lee Sung Hwa Bae Young Rok Do Won Sik Lee Min Kyung Kim Jina Jung Jung Min Lee Ju-Hyung Kim Dong Won Baek Sang-Kyun Sohn Joon Ho Moon |
| author_sort | Hee Jeong Cho |
| collection | DOAJ |
| description | Background/Aims Daratumumab has shown an encouraging antitumor effect in patients with multiple myeloma (MM), and was known to alter the immune properties by off-targeting immunosuppressive cells. Here, we aimed to evaluate the change in absolute lymphocyte count (ALC) as a surrogate marker for predicting survival outcomes of patients treated with daratumumab. Methods Between 2018 and 2021, the medical records of patients with relapsed/refractory MM (RRMM) treated with daratumumab monotherapy at 10 centers in South Korea were reviewed. We collected the ALC data at pre-infusion (D0), day 2 after the first infusion (D2), and prior to the third cycle of daratumumab therapy (D56). Results Fifty patients who were administered at least two cycles of daratumumab were included. Overall response rate was 54.0% after two cycles of daratumumab treatment. On D2, almost all patients experienced a marked reduction in ALC. However, an increase in ALC on D56 (ALCD56) was observed in patients with non-progressive disease, whereas failure of ALC recovery was noted in those with progressive disease. Patients with ALCD56 > 700/μL (n = 39, 78.0%) had prolonged progression-free survival (PFS) and overall survival (OS) than those with ALCD56 ≤ 700/μL (median PFS: 5.8 months vs. 2.6 months, p = 0.025; median OS: 24.1 months vs. 6.1 months, p = 0.004). In addition, ALCD56 >700/μL was a significant favorable prognostic factor for PFS (hazard ratio [HR], 0.22; p = 0.003) and OS (HR, 0.23; p = 0.012). Conclusions Increase in ALC during daratumumab treatment was significantly associated with prolonged survival outcomes in patients with RRMM. The ALC value can predict clinical outcomes in patients treated with daratumumab. |
| first_indexed | 2024-04-10T06:03:03Z |
| format | Article |
| id | doaj.art-ae24d4e0897248d2a9eeeb9acb663e6d |
| institution | Directory Open Access Journal |
| issn | 1226-3303 2005-6648 |
| language | English |
| last_indexed | 2024-04-10T06:03:03Z |
| publishDate | 2023-03-01 |
| publisher | The Korean Association of Internal Medicine |
| record_format | Article |
| series | The Korean Journal of Internal Medicine |
| spelling | doaj.art-ae24d4e0897248d2a9eeeb9acb663e6d2023-03-03T07:00:11ZengThe Korean Association of Internal MedicineThe Korean Journal of Internal Medicine1226-33032005-66482023-03-0138223824710.3904/kjim.2022.183170768Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myelomaHee Jeong Cho0Jae-Cheol Jo1Yoo Jin Lee2Myung Won Lee3Do Young Kim4Ho Jin Shin5Sung Nam Im6Ji Hyun Lee7Sung Hwa Bae8Young Rok Do9Won Sik Lee10Min Kyung Kim11Jina Jung12Jung Min Lee13Ju-Hyung Kim14Dong Won Baek15Sang-Kyun Sohn16Joon Ho Moon17 Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea Department of Hematology-Oncology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea Department of Hematology-Oncology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea Department of Hematology-Oncology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea Department of Hematology-Oncology, Inje University Haeundae Paik Hospital, Busan, Korea Department of Hematology-Oncology, Dong-A University Hospital, Busan, Korea Department of Hematology-Oncology, Daegu Catholic University Hospital, Daegu Catholic University School of Medicine, Daegu, Korea Department of Hematology-Oncology, Keimyung University School of Medicine, Daegu, Korea Department of Hematology-Oncology, Inje University Busan Paik Hospital, Busan, Korea Department of Hematology-Oncology, Yeungnam University Hospital, Daegu, Korea Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, KoreaBackground/Aims Daratumumab has shown an encouraging antitumor effect in patients with multiple myeloma (MM), and was known to alter the immune properties by off-targeting immunosuppressive cells. Here, we aimed to evaluate the change in absolute lymphocyte count (ALC) as a surrogate marker for predicting survival outcomes of patients treated with daratumumab. Methods Between 2018 and 2021, the medical records of patients with relapsed/refractory MM (RRMM) treated with daratumumab monotherapy at 10 centers in South Korea were reviewed. We collected the ALC data at pre-infusion (D0), day 2 after the first infusion (D2), and prior to the third cycle of daratumumab therapy (D56). Results Fifty patients who were administered at least two cycles of daratumumab were included. Overall response rate was 54.0% after two cycles of daratumumab treatment. On D2, almost all patients experienced a marked reduction in ALC. However, an increase in ALC on D56 (ALCD56) was observed in patients with non-progressive disease, whereas failure of ALC recovery was noted in those with progressive disease. Patients with ALCD56 > 700/μL (n = 39, 78.0%) had prolonged progression-free survival (PFS) and overall survival (OS) than those with ALCD56 ≤ 700/μL (median PFS: 5.8 months vs. 2.6 months, p = 0.025; median OS: 24.1 months vs. 6.1 months, p = 0.004). In addition, ALCD56 >700/μL was a significant favorable prognostic factor for PFS (hazard ratio [HR], 0.22; p = 0.003) and OS (HR, 0.23; p = 0.012). Conclusions Increase in ALC during daratumumab treatment was significantly associated with prolonged survival outcomes in patients with RRMM. The ALC value can predict clinical outcomes in patients treated with daratumumab.http://www.kjim.org/upload/kjim-2022-183.pdfmultiple myelomadaratumumablymphocyte countbiomarkerssurvival analysis |
| spellingShingle | Hee Jeong Cho Jae-Cheol Jo Yoo Jin Lee Myung Won Lee Do Young Kim Ho Jin Shin Sung Nam Im Ji Hyun Lee Sung Hwa Bae Young Rok Do Won Sik Lee Min Kyung Kim Jina Jung Jung Min Lee Ju-Hyung Kim Dong Won Baek Sang-Kyun Sohn Joon Ho Moon Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma The Korean Journal of Internal Medicine multiple myeloma daratumumab lymphocyte count biomarkers survival analysis |
| title | Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma |
| title_full | Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma |
| title_fullStr | Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma |
| title_full_unstemmed | Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma |
| title_short | Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma |
| title_sort | predictive role of absolute lymphocyte count in daratumumab treated patients with relapsed refractory multiple myeloma |
| topic | multiple myeloma daratumumab lymphocyte count biomarkers survival analysis |
| url | http://www.kjim.org/upload/kjim-2022-183.pdf |
| work_keys_str_mv | AT heejeongcho predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT jaecheoljo predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT yoojinlee predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT myungwonlee predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT doyoungkim predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT hojinshin predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT sungnamim predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT jihyunlee predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT sunghwabae predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT youngrokdo predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT wonsiklee predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT minkyungkim predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT jinajung predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT jungminlee predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT juhyungkim predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT dongwonbaek predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT sangkyunsohn predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma AT joonhomoon predictiveroleofabsolutelymphocytecountindaratumumabtreatedpatientswithrelapsedrefractorymultiplemyeloma |